

# Cell-to-Cell Measles Virus Spread between Human Neurons Is Dependent on Hemagglutinin and Hyperfusogenic Fusion Protein

佐藤, 裕真

<https://hdl.handle.net/2324/1931825>

---

出版情報 : Kyushu University, 2017, 博士 (医学), 課程博士

バージョン :

権利関係 : Public access to the fulltext file is restricted for unavoidable reason (2)

1 Cell-to-cell measles virus spread between human neurons dependent on the  
2 hemagglutinin and the hyperfusogenic fusion protein

3

4 Yuma Sato<sup>1</sup>, Shumpei Watanabe<sup>1,2</sup>, Yoshinari Fukuda<sup>1</sup>, Takao Hashiguchi<sup>1</sup>,  
5 Yusuke Yanagi<sup>1#</sup>, Shinji Ohno<sup>1,3#</sup>

6

7 <sup>1</sup>Department of Virology, Faculty of Medicine, Kyushu University, Fukuoka,  
8 Japan

9 <sup>2</sup>Special Pathogens Laboratory, Department of Virology I, National Institute of  
10 Infectious Diseases, Tokyo, Japan

11 <sup>3</sup>Department of Virology, Graduate School of Medicine, University of the  
12 Ryukyus, Okinawa, Japan

13

14 Running Title: Measles virus spread between human neurons

15

16

17

18 # Address Correspondence to  
19 Yusuke Yanagi, [yyanagi@virology.med.kyushu-u.ac.jp](mailto:yyanagi@virology.med.kyushu-u.ac.jp) or  
20 Shinji Ohno, [soono@med.u-ryukyu.ac.jp](mailto:soono@med.u-ryukyu.ac.jp)

21

22 Abstract: 247 words

23 Importance: 146 words

24 Text: 3916 words

25

26

27

28

29

30

31

32

33

34

35 **Abstract**

36 Measles virus (MV) usually causes acute infection, but in rare cases persists in  
37 the brain, resulting in subacute sclerosing panencephalitis (SSPE). Since  
38 human neurons, an important target affected in the disease, do not express the  
39 known MV receptors (signaling lymphocyte activation molecule (SLAM) and  
40 nectin 4), how MV infects neurons and spreads between them is unknown.  
41 Recent studies have shown that many virus strains isolated from SSPE patients  
42 possess substitutions in the extracellular domain of the fusion (F) protein which  
43 confer enhanced fusion activity. Hyperfusogenic viruses with such mutations,  
44 unlike the wild-type MV, can induce cell-cell fusion even in SLAM<sup>-</sup> and nectin  
45 4-negative cells and spread efficiently in human primary neurons and the  
46 brains of animal models. We here show that a hyperfusogenic mutant MV  
47 (IC323-F(T461I)-EGFP), but not the wild-type MV, spreads in differentiated  
48 NT2 cells, a widely-used human neuron model. Confocal time-lapse imaging  
49 revealed the cell-to-cell spread of IC323-F(T461I)-EGFP between NT2 neurons  
50 without syncytium formation. The production of virus particles was strongly  
51 suppressed in NT2 neurons, also supporting the cell-to-cell viral transmission.

52 The spread of IC323-F(T461D)-EGFP was inhibited by the fusion inhibitor  
53 peptide as well as by some but not all of anti-hemagglutinin antibodies which  
54 neutralize SLAM- or nectin-4-dependent MV infection, suggesting the presence  
55 of a distinct neuronal receptor. Our results indicate that MV spreads in a  
56 cell-to-cell manner between human neurons without causing syncytium  
57 formation, and that the spread is dependent on the hyperfusogenic F protein,  
58 the hemagglutinin and the putative neuronal receptor for MV.

59

## 60 **Importance**

61 Measles virus (MV), in rare cases, persists in the human central nervous system  
62 (CNS) and causes subacute sclerosing panencephalitis (SSPE) several years  
63 after acute infection. This neurological complication is almost always fatal, and  
64 there is currently no effective treatment for it. Mechanisms by which MV  
65 invades the CNS and causes the disease remain to be elucidated. We have  
66 previously shown that fusion-enhancing substitutions in the fusion protein of  
67 MVs isolated from SSPE patients contribute to MV spread in neurons. In this  
68 study, we demonstrate that MV bearing the hyperfusogenic mutant fusion

69 protein spreads between human neurons in a cell-to-cell manner. Spread of the  
70 virus was inhibited by the fusion inhibitor peptide and antibodies against the  
71 MV hemagglutinin, indicating that both the hemagglutinin and hyperfusogenic  
72 fusion protein play important roles in MV spread between human neurons. The  
73 findings help us better understand the disease process of SSPE.

74

## 75 **Introduction**

76 Measles, characterized by high fever, conjunctivitis and a maculopapular rash,  
77 is caused by measles virus (MV), a highly contagious human pathogen (1).  
78 Effective live vaccines have greatly reduced its morbidity and mortality, but  
79 measles is still prevalent in certain developing countries (2). MV rarely  
80 establishes persistent infection in the central nervous system (CNS), and  
81 several years after acute infection, 6.5 to 11 cases per 100,000 cases of measles  
82 develop subacute sclerosing panencephalitis (SSPE) (3) and the risk of  
83 developing SSPE is much higher for children contracting measles infection  
84 below 5 years of age (4). Patients with SSPE exhibit characteristic clinical  
85 manifestations such as personality changes, myoclonus and dementia, and

86 there is currently no effective treatment for the disease (5).

87 MV is a member of the genus *Morbillivirus* of the family  
88 *Paramyxoviridae*, and possesses a non-segmented, negative-sense RNA genome  
89 with 6 genes encoding the nucleocapsid (N), phospho- (P), matrix (M), fusion (F),  
90 hemagglutinin (H), and large (L) proteins, respectively (1). The P gene also  
91 encodes non-structural proteins V and C. The N protein encapsidates the viral  
92 genome, forming the nucleocapsid, which is bound by the RNA-dependent RNA  
93 polymerase comprised of the L and P proteins. This ribonucleoprotein (RNP)  
94 complex binds to the M protein, which interacts with cytoplasmic tails of the H  
95 and F proteins and is responsible for the assembly of virus particles. The H and  
96 F proteins are envelope glycoproteins, and mediate receptor binding and  
97 membrane fusion, respectively. Binding of the H protein to a cellular receptor  
98 induces conformational changes of the F protein, leading to the virus-cell fusion  
99 and virus entry into the cell (6, 7). In addition, the expression of the H and F  
100 proteins on the cell surface causes the cell-cell fusion between infected and  
101 adjacent cells, producing multinucleated giant cells (syncytia).

102 The cellular receptors for MV are signaling lymphocyte activation

103 molecule (SLAM) expressed on immune cells (8, 9) and nectin 4 on epithelial  
104 cells (10, 11). Since human neurons, an important target affected in SSPE,  
105 express neither SLAM nor nectin 4 (12, 13), MV is thought to infect neurons  
106 differently from non-neuronal target cells. Furthermore, free virus particles are  
107 not usually detected in the brains of SSPE patients although viral RNA and  
108 proteins are present (14-17). The Edmonston strain of MV (a  
109 laboratory-adapted strain) can use ubiquitously expressed CD46 as an  
110 additional receptor, through the mutations in the H gene (18, 19). It has been  
111 shown that the Edmonston strain can infect and spread between primary  
112 hippocampal neurons from CD46 transgenic mice that express human CD46 on  
113 neurons (20). The transmission of the Edmonston strain between neurons was  
114 blocked by the fusion inhibitor peptide (FIP) (21), and the virus could spread  
115 from CD46<sup>+</sup> to CD46<sup>-</sup> neurons in a cell-cell contact-dependent manner (20). The  
116 authors proposed that only the F protein mediates the spread of MV between  
117 neurons and that the H protein is dispensable for the process (21, 22). The  
118 Edmonston strain was also shown to spread between rat hippocampal neurons  
119 (23).



120           MVs recovered from brain tissues of SSPE patients (SSPE strains)  
121 contain characteristic features in their genomes. The function and expression of  
122 the M protein are impaired in most SSPE strains by such mechanisms as A-to-G  
123 hypermutations and read-through between the P and M genes (24-26). Because  
124 these mutations lead to the lower production of virus particles and possible  
125 evasion of the recognition by the host immune system, the defect of the M  
126 protein has been thought to contribute to neurovirulence (26, 27). The defective  
127 nature of the M protein also affects its ability to modulate viral RNA synthesis  
128 allowing enhanced transcription of the genome (28, 29). Furthermore, most  
129 SSPE strains have alterations in the cytoplasmic tail of the F protein (30, 31).  
130 Mutations causing the defect of the M protein or producing shortened  
131 cytoplasmic tails of the F and H proteins were shown to endow MV with  
132 hyperfusogenicity and facilitate MV spread in the brains of genetically modified  
133 mice (27).

134           More recent studies have shown that many SSPE strains possess amino  
135 acid substitutions in the extracellular domain of the F protein, which confer  
136 enhanced fusion activity in SLAMF4- or nectin 4-expressing cells (32, 33).

137 Importantly, recombinant MVs possessing these substitutions in the F protein,  
138 but not the wild-type MV, cause syncytium formation even in SLAMF4- and nectin  
139 4-negative cells including human neuroblastoma cell lines, and spread  
140 efficiently in the brains of the type I interferon receptor subunit 1 (IFNAR1)  
141 knockout mice and suckling hamsters as well as in human primary neurons (33,  
142 34). The H protein of SSPE strains was also shown to be partly responsible for  
143 neurovirulence (32, 35, 36).

144 In the present study, we aimed to examine how MV is transmitted  
145 between neurons, by using cells and viruses relevant to MV infection in human  
146 brains. To this end, we employed NTERA-2 cl. D1 (NT2), a human embryonal  
147 carcinoma cell line, which can be differentiated into postmitotic neurons  
148 following the treatment with retinoic acid (RA) (37-40). Removal of  
149 undifferentiated cells by mitotic inhibitors increases the proportion of  
150 differentiated neurons up to 95% (40). These cells express several  
151 neurotransmitters (41), exhibit neuronal electrophysiological properties (42),  
152 and have been used as human model neurons in the fields of basic sciences,  
153 drug screening and clinical application (43). SSPE strains accumulate many

154 mutations during persistence, but generally do not have those in the H gene  
155 that would allow them to utilize CD46 as a receptor (18, 44-46). Thus, we used  
156 for this study the wild-type strain-based recombinant MV and its mutant  
157 possessing an SSPE strain-derived substitution in the F protein.

158

## 159 **Results**

160 **Spread of the hyperfusogenic MV between NT2 neurons.** Enhanced green  
161 fluorescent protein (EGFP)-expressing recombinant MVs possessing  
162 fusion-enhancing substitutions in the F protein [e.g. IC323-F(T461D)-EGFP],  
163 but not the parental MV possessing the wild-type F protein (IC323-EGFP),  
164 efficiently spread in human primary neurons (34). To investigate mechanisms of  
165 MV spread between human neurons in detail, we used human NT2 neurons  
166 (NT2N), which are more tractable than primary neurons. Undifferentiated NT2  
167 cells were differentiated into postmitotic neurons using the cell aggregate  
168 method (40) (Fig. 1A). NT2N cells had small, phase-bright cell bodies and long  
169 axons, and tended to form clusters, as previously reported (40). Expression  
170 levels of several neuronal marker genes were greatly increased in NT2N cells

171 compared to undifferentiated cells (Fig. 1B). A small number of larger glia-like  
172 cells were also present in the postmitotic cell population, but expression levels  
173 of astrocytic marker genes were not elevated significantly compared to  
174 undifferentiated cells (Fig. 1A, B).

175           To examine the effect of the fusion-enhancing substitution T461I in the  
176 F protein on the spread of MV between neurons, NT2N cells were infected with  
177 IC323-EGFP or IC323-F(T461I)-EGFP at a multiplicity of infection (MOI) of 2  
178 (Fig. 2A). NT2N cells were also infected with VSV $\Delta$ G\*-G, which contains the  
179 GFP gene in its genome and does not produce infectious particles because it  
180 lacks the glycoprotein (G) gene (47), at an MOI of 0.05. Single infected cells were  
181 observed one day after infection with any of the three viruses. At 2 days post  
182 infection (d.p.i.), expression of EGFP was largely restricted to cells originally  
183 infected with IC323-EGFP and hardly spread further. By contrast, expression of  
184 EGFP spread efficiently from neurons infected with IC323-F(T461I)-EGFP to  
185 adjacent cells, without syncytium formation (Fig. 2A). The spread of GFP  
186 expression was never observed in VSV $\Delta$ G\*-G-infected neurons, indicating that  
187 GFP per se cannot be transmitted between neurons. In addition, larger increase

188 in the expression of the MV-N protein was observed over time in neurons  
189 infected with IC323-F(T461D)-EGFP, compared with those infected with  
190 IC323-EGFP (Fig. 2B). Taken together, these results indicate that the  
191 fusion-enhancing substitution in the F protein is critical for efficient spread of  
192 MV in NT2N cells, and that the viral genome is indeed transmitted from  
193 neurons infected with the hyperfusogenic MV to adjacent neurons. After MV  
194 infection, we continued to observe EGFP-positive infected NT2N cells, which  
195 appeared to be damaged and died at 4-6 d.p.i. (data not shown).

196 **The hyperfusogenic MV spreads between NT2 neurons in a cell-to-cell**  
197 **manner.** To examine how the hyperfusogenic MV spreads between NT2N cells,  
198 we next performed a confocal time-lapse photography (Fig. 3A and Movie S1).  
199 NT2N cells were infected with IC323-F(T461D)-EGFP, and observed under a  
200 confocal microscope. At 24 h p.i., a small number of NT2N cells were  
201 EGFP-positive. During observation, expression of EGFP efficiently spread from  
202 originally infected neurons to those connected to them via axons, and the  
203 number of EGFP-positive neurons increased over time.

204 IC323-F(T461D)-EGFP was reported to propagate in SLAM- or nectin

205 4-expressing cells at comparable levels with the wild-type MV until 48 h p.i  
206 (thereafter its titers decrease sharply due to strong cytopathic effects) (34). In  
207 contrast, it produced only low virus titers in NT2N cells for 4 days after  
208 infection (Fig. 3B), despite its efficient spread between the cells. The results,  
209 together with the above morphological findings, indicate that the  
210 hyperfusogenic virus spreads between NT2N cells mainly, if not exclusively, in a  
211 cell-to-cell manner.

212 **Membrane fusion is involved in the spread of the hyperfusogenic MV**  
213 **between NT2N cells.** While IC323-F(T461D)-EGFP induced syncytium formation  
214 in SLAM<sup>-</sup> and nectin 4-negative non-neuronal cells (e.g. Vero cells), it did not in  
215 human primary neurons and NT2N cells ((33, 34) and this study). However, it is  
216 possible that a small membrane fusion occurs between infected and adjacent  
217 cells, contributing to the spread of MV. To test this idea, we used FIP, which is  
218 known to inhibit membrane fusion induced by MV (48, 49). Vero cells expressing  
219 human SLAM (Vero/hSLAM) and NT2N cells were infected with  
220 IC323-F(T461D)-EGFP at an MOI of 0.1 for 1 h, and then incubated in the  
221 presence of FIP or the solvent dimethyl sulfoxide (DMSO). While Vero/hSLAM

222 cells treated with DMSO formed extensive syncytia at 1 d.p.i., FIP strongly  
223 inhibited cell-cell fusion in them (Fig. 4). Remarkably, FIP completely blocked  
224 the spread of IC323-F(T461D)-EGFP between NT2N cells, while DMSO had no  
225 effect on the spread. The results suggest that membrane fusion is indeed  
226 involved in the cell-to-cell spread of the hyperfusogenic MV between NT2N cells.  
227 We also tested substance P, which was reported to inhibit membrane fusion  
228 induced by MV (48, 49) and neuronal spread of the Edmonston strain (21).  
229 Substance P inhibited neither syncytium formation in Vero/hSLAM cells nor the  
230 spread of IC323-F(T461D)-EGFP between NT2N cells (data not shown).

231       **The H protein is required for the cell-to-cell spread of the**  
232 **hyperfusogenic virus between NT2N cells.** To examine whether the H protein is  
233 involved in MV spread between NT2N cells, we generated anti-H monoclonal  
234 antibodies (MAbs) that can block SLAM- and nectin 4-dependent MV infection.  
235 Vero/hSLAM cells and Vero cells expressing human nectin 4 (Vero/hNectin4)  
236 were infected with IC323-EGFP, and NT2N cells with IC323-F(T461D)-EGFP at  
237 an MOI of 0.1 for 1 h. The infected cells were then incubated in the presence of a  
238 previously reported anti-H MAb 2F4 (50) or anti-H MAbs we generated (7C6,

239 8F6, and 10B5) and observed under a fluorescence microscope (Fig. 5A). The  
240 extents of syncytium formation or viral spread were also determined by  
241 quantitating EGFP-positive areas (Fig. 5B). All four MAbs examined inhibited,  
242 albeit to different extents, syncytium formation in IC323-EGFP-infected  
243 Vero/hSLAM and Vero/hNectin4 cells (Fig. 5A, B). When these cells were  
244 infected with the hyperfusogenic IC323-F(T461D)-EGFP, all the MAbs also  
245 exhibited inhibitory activity though to the lesser degree (data not shown). MAbs  
246 2F4 and 8F6 were also able to inhibit the spread of IC323-F(T461D)-EGFP  
247 between NT2N cells, whereas 7C6 failed to do so (Fig. 5A, B). 10B5 exhibited a  
248 weaker ability to inhibit syncytium formation in Vero/hSLAM and  
249 Vero/hNectin4 cells than the other three MAbs, but it completely blocked the  
250 spread of IC323-F(T461D)-EGFP between NT2N cells (Fig. 5A, B).

251

## 252 **Discussion**

253 In this study, we demonstrated that the hyperfusogenic IC323-F(T461D)-EGFP,  
254 but not the parental wild-type IC323-EGFP, spread efficiently between human  
255 neuron NT2N cells. The finding is consistent with our previous results obtained



256 with this and other hyperfusogenic recombinant MVs in human primary neuron  
257 culture and in the brains of suckling hamsters and IFNAR1 knockout mice (33,  
258 34). Thus, enhanced fusion activity of the F protein appears to be essential for  
259 efficient spread of MV in human and rodent neurons.

260           On the other hand, the Edmonston strain of MV has been shown to  
261 spread between mouse (20) and rat neurons (23), without fusion-enhancing  
262 substitutions in the F protein. The Edmonston strain has many substitutions in  
263 the receptor-binding H protein including those allowing the use of CD46 as a  
264 receptor (18, 19). However, CD46 is not critically involved in the spread of the  
265 Edmonston strain because neurons from rats and CD46 non-transgenic mice do  
266 not express CD46. At present there is no knowing whether the molecule  
267 involved in the spread of the Edmonston strain between rodent neurons is the  
268 same as the one used for MV spread between human neurons. Furthermore,  
269 expression of CD46 on human neurons makes it difficult to interpret the results  
270 obtained with the Edmonston strain. To avoid these problems and study what  
271 indeed occurs in the human brain, we employed human neurons derived from  
272 NT2 cells and wild-type MV-based recombinant viruses.

273           Because SLAM and nectin 4 are not expressed on human neurons, it is  
274 likely that MV uses other molecule(s) to enter and spread between neurons.  
275 Given that fusion-enhancing substitutions in the F protein strongly promote  
276 MV spread between human neurons, only the F protein, but not the H protein,  
277 may play a role in MV spread, as previously proposed (21, 22). However, most of  
278 anti-H MAbs (neutralizing infection via SLAM or nectin4) examined blocked the  
279 spread of IC323-F(T461D)-EGFP between NT2N cells. One MAb neutralized  
280 SLAM- and nectin 4-dependent MV infections, but did not inhibit the spread of  
281 IC323-F(T461D)-EGFP between NT2N cells. Another MAb only weakly inhibited  
282 syncytium formation in Vero/hSLAM and Vero/hNectin4 cells, but strongly  
283 blocked the spread of IC323-F(T461D)-EGFP between NT2N cells. These results  
284 suggest that the H protein is also required for the spread of the hyperfusogenic  
285 MV between NT2N cells, and that the region on the H protein involved in MV  
286 spread between neurons is overlapping with but different from that involved in  
287 the interaction with SLAM or nectin 4. Furthermore, these findings indicate the  
288 presence of the neuronal receptor interacting with the H protein of MV. In the  
289 sera and cerebrospinal fluids of SSPE patients, high levels of anti-MV Abs are

290 present (5). This means that MV can somehow escape from neutralization by  
291 these Abs in SSPE patients. Detailed analyses of amino acid substitutions in  
292 the H protein from SSPE strains may reveal the mechanisms by which MV  
293 spreads in the CNS in the presence of anti-H Abs.

294         In SSPE patients, MV persistently infects neurons without producing  
295 virus particles (14). The lack of virus production is attributed to the defect of the  
296 M protein (26, 27). Thus, it is thought that the cell-to-cell MV transmission  
297 occurs between neurons in the brains of SSPE patients. By using confocal  
298 time-lapse imaging, we observed the cell-to-cell spread of IC323-F(T461D)-EGFP  
299 between NT2N cells. The virus was found to spread from originally infected  
300 neurons to those connected to them via axons. Furthermore, little virus  
301 production was detected in NT2N cells, although IC323-F(T461D)-EGFP  
302 possesses the intact M gene unlike most SSPE strains. Similarly, the  
303 Edmonston strain (possessing the intact M protein) was reported to grow well in  
304 undifferentiated NT2 cells (presumably using CD46 as a receptor), but not in  
305 NT2 neurons (20). Thus, mutations in the M gene, a hallmark of SSPE strains,  
306 may partly result from the dispensability of the M protein for their survival in

307 neurons.

308 IC323-F(T461D)-EGFP did not induce syncytia in NT2N cells like in  
309 human primary neurons (34). However, its spread between NT2N cells was  
310 prevented by FIP, indicating that the cell-cell fusion does occur when the virus  
311 is transmitted. This is consistent with the clinical observation that syncytia are  
312 not present in the brains of SSPE patients (5). In the human brain, the cell-cell  
313 contacts between neurons may be hindered by other supporting cells and  
314 myelinated nerve fibers, and limited to small areas such as synapses. This  
315 spatial arrangement may be a reason why neurons do not form syncytia in  
316 SSPE patients. In our culture of NT2N cells, non-neuronal cells are very few,  
317 and the cell-cell contact appears to occur between cell bodies of different  
318 neurons. Thus, in NT2N cells, the membrane fusion may occur only at synapses  
319 where virus (RNP complex) transmission takes place between neurons, but may  
320 not occur in other parts of cells. Recently, it has been shown that peptides  
321 derived from the heptad repeat regions of the F protein can inhibit entry and  
322 cell fusion by MV, and protect model mice from MV-induced encephalitis (51-53).  
323 A fusion-enhancing substitution in the F protein was also found in MV genomes

324 from the brains of human immunodeficiency virus-infected patients with  
325 measles inclusion body encephalitis (54). Blocking of membrane fusion caused  
326 by mutant F proteins might be a good strategy to inhibit progression of fatal MV  
327 infection in the CNS.

328 In conclusion, the H protein and the mutant F protein possessing  
329 fusion-enhancing substitutions play crucial roles in membrane fusion and  
330 subsequent MV transmission between neurons. Our data also suggest that a  
331 molecule(s) other than SLAM and nectin 4 acts as a neuronal receptor for MV.  
332 We envisage that this putative receptor is highly concentrated at synapses.

333

## 334 **Materials and Methods**

335 **Cells.** Vero/hSLAM (9) and Vero/hNectin4 cells (55) were maintained in  
336 Dulbecco's modified Eagle's medium (DMEM; Wako Pure Chemical Industries)  
337 supplemented with 7.5% fetal bovine serum (FBS; Sigma) and 1%  
338 penicillin-streptomycin (Gibco). NTERA-2 cl. D1 (NT2) cells were purchased  
339 from American Type Culture Collection and maintained in Opti-MEM (Gibco)  
340 supplemented with 5% FBS and 1% penicillin-streptomycin. We slightly

341 modified the previously described protocol for neuronal differentiation of NT2  
342 cells (40). Briefly, NT2 cells were suspended in DMEM supplemented with 10%  
343 FBS, and seeded in bacteriological grade Petri dishes (Eiken Chemical) at a  
344 density of  $4\text{--}5 \times 10^6$  cells per dish. On the next day, all-trans RA (Sigma) was  
345 added to culture medium at a final concentration of 10  $\mu\text{M}$ . Every 2–3 days the  
346 medium and dishes were changed. After 7–8 days, the cells were seeded in  
347 10-cm cell culture dishes (Nippon Genetics) and cultured for another 6–8 days.  
348 The cells were detached by trypsin (MP biomedical), transferred to 15-cm cell  
349 culture dishes (Nunc), and cultured without RA for 2 days. The cells were  
350 trypsinized again, seeded in 10-cm cell culture dishes precoated with 10  $\mu\text{g}$  of  
351 poly-D-lysine (PDL; Sigma)/mL, 10  $\mu\text{g}$  of laminin (LAM; Sigma)/mL and 0.1%  
352 gelatin (Sigma), and supplied with medium containing a final concentration of  
353 40  $\mu\text{M}$  Cytosine  $\beta$ -D-Arabinofuranoside (Ara-C; Sigma) and 4  $\mu\text{M}$  Uridine  
354 (Sigma). After 7–10 days, differentiated neurons (NT2N) were detached by brief  
355 trypsinization and seeded in plates precoated with PDL, LAM, and gelatin for  
356 further experiments.

357 **Viruses.** IC323-EGFP is a recombinant MV expressing EGFP based on

358 the wild-type IC-B strain (56, 57). IC323-F(T461I)-EGFP was generated, based  
359 on IC323-EGFP (33). The recombinant MVs were prepared as described (58)  
360 and titrated on Vero/hSLAM cells by plaque assay. VSV $\Delta$ G\*-G was prepared  
361 and titrated on 293T cells as previously described (47, 59).

362 **Confocal time-lapse imaging.** NT2N cells seeded in glass-bottom dishes  
363 (Matsunami Glass Ind.) were infected with IC323-F(T461I)-EGFP at an MOI of  
364 2. EGFP fluorescence was observed under a confocal microscope (Radiance  
365 2100; Bio-Rad). Images were taken every 15 min from 24 h p.i. to 40 h p.i.

366 **Inhibition of virus spread by FIP.** FIP (Z-D-Phe-Phe-Gly; Peptide  
367 institute) and substance P  
368 (H-Arg-Pro-Lys-Pro-Gln-Gln-Phe-Phe-Gly-Leu-Met-NH<sub>2</sub>; Peptide institute)  
369 were dissolved in DMSO (Sigma). Vero/hSLAM and NT2N cells seeded in  
370 24-well plates were infected with IC323-F(T461I)-EGFP at an MOI of 0.1. At 1 h  
371 p.i., DMSO, FIP, or substance P was added to the culture medium at a final  
372 concentration of 2% (DMSO) or 200  $\mu$ M (FIP and substance P).

373 **Inhibition of virus spread by anti-H MAbs.** MAb 2F4 is a previously  
374 described antibody against MV-H (50). To generate anti-H MAbs, the expression

375 plasmid encoding soluble histidine (His)-tagged MV-H was transiently  
376 transfected into HEK293S GnTI(-) cells (60, 61). One week after transfection,  
377 culture medium containing the secreted MV-H was collected. MV-H was purified  
378 by using the Ni<sup>2+</sup>-NTA affinity column (cOmplete His-Tag Purification Resin;  
379 Roche) and superdex 200 GL 10/300 gel filtration chromatography (GE  
380 Healthcare). Six-week-old BALB/c mice were immunized with the purified  
381 MV-H four times at intervals of 1 week. Three days after the last immunization,  
382 the mice were euthanized, and spleen cells were harvested. All animal  
383 experiments were reviewed by the Institutional Committee of Ethics on Animal  
384 Experiments and carried out according to the Guidelines for Animal  
385 Experiments of the Faculty of Medicine, Kyushu University, Japan. We  
386 screened hybridoma cells for anti-H MAbs possessing neutralizing ability for  
387 MV. Vero/hSLAM and Vero/hNectin4 cells were infected with IC323-EGFP  
388 mixed with supernatants of hybridomas, and at 1 h p.i., FIP was added to the  
389 culture medium. At 24-36 h p.i., EGFP fluorescence was observed under a  
390 fluorescence microscope (Axiovert 200; Carl Zeiss). MV-neutralizing MAbs were  
391 purified by protein G affinity chromatography. We verified by enzyme-linked



392 immunosorbent assay that all purified MV-neutralizing MAbs could bind to  
393 MV-H. Vero/hSLAM, Vero/hNectin4 and NT2N cells were seeded in 96-well  
394 plates and infected with IC323-EGFP or IC323-F(T461I)-EGFP at an MOI of 0.1.  
395 At 1 h p.i., anti-H MAbs were added to the culture medium at a final  
396 concentration of 10 µg/mL. Fluorescence images of cells were taken with  
397 BZ-X710 (Keyence) at 48 h p.i. Relative areas of EGFP-expressing cells in  
398 triplicate samples were determined using BZ-X Analyzer (Keyence).

399         **Reverse transcription-quantitative PCR (RT-qPCR).** RNA was extracted  
400 with TRIzol (Invitrogen) from undifferentiated NT2 cells and postmitotic  
401 neurons (NT2 cells treated with RA for 2 weeks and mitotic inhibitors for  
402 another 1 week). The RNA samples were treated with RQ1 RNase-Free DNase  
403 (Promega) and reverse transcribed using PrimeScript RT reagent Kit (Takara  
404 Bio). Quantification of mRNAs of neuronal and astrocytic markers and  
405 glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was carried out using  
406 SYBR Premix Ex Taq II (Takara Bio) and LightCycler 1.5 (Roche). For  
407 microtubule-associated protein 2 (MAP2), microtubule-associated protein tau  
408 (MAPT), RNA binding protein Fox-1 homolog 3 (RBFOX3), class III beta-tubulin

409 (TUBB3), glial fibrillary acidic protein (GFAP), and glutamate-ammonia ligase  
410 (GLUL), we used primer pairs 5'-TTTGGGCACACTCTTGTTGC-3' and  
411 5'-TTGCTTCCGTTGGCATTTCG-3', 5'-CAGACCTGAAGAATGTCAAGTCC-3'  
412 and 5'-ACACTTGGAGGTCACCTTGC-3', 5'-GCAAATGTTCTGGGCAATTTCG-3'  
413 and 5'-ATCGTCCCATTTCAGCTTCTCC-3', 5'-TCATCAGTGATGAGCATGGC-3'  
414 and 5'-TCGTTGTAGTAGACGCTGATCC-3', 5'-ACTCAATGCTGGCTTCAAGG-3'  
415 and 5'-AGCGAACCTTCTCGATGTAGC-3', and  
416 5'-ATGCTGGAGTCAAGATTGCG-3' and 5'-AGTCTTCACACACACGATGC-3',  
417 respectively. Data were analyzed by a two-tailed Student's t test.

418 **Western blotting.** NT2N cells seeded in 12-well plates were infected with  
419 IC323-EGFP or IC323-F(T461D)-EGFP at an MOI of 2. The cells were washed by  
420 phosphate-buffered saline (PBS) and lysed in 1 × sodium dodecyl sulfate (SDS)  
421 loading buffer (40mM Tris HCl pH6.8, 1.6% SDS, 8% glycerol, 0.05%  
422 Bromophenol Blue, 0.1M dithiothreitol). Proteins in the lysate were separated  
423 by SDS-polyacrylamide gel electrophoresis (PAGE), and transferred to  
424 polyvinylidene difluoride membranes (Millipore). The membranes were blocked  
425 with PBS containing 0.05% Tween 20 and 5% skimmed milk, and subsequently

426 incubated with anti-MV serum for detection of MV-N (kindly provided by M. B.  
427 A. Oldstone) (62) or mouse anti-actin MAb (sc-8432; Santa Cruz Biotechnology).  
428 After washing with PBS-Tween 20 (PBS-T) three times, the membranes were  
429 incubated with goat anti-human IgG-horseradish peroxidase (HRP) or goat  
430 anti-mouse IgG-HRP (Jackson ImmunoResearch), washed by PBS-T three  
431 times again, and treated with Chemi-Lumi One Super (Nacalai Tesque).  
432 Chemiluminescent signals were detected by VersaDoc 5000 (Bio-Rad).

433

#### 434 **Acknowledgements**

435 We thank M. B. A. Oldstone for providing the reagent. This study was supported  
436 by grants from the Ministry of Health, Labor and Welfare (the Research  
437 Committee of Prion Disease and Slow Virus Infection) of Japan (YY), by JSPS  
438 KAKENHI grant number 24115005 (YY), by AMED J-PRIDE grant number  
439 17fm0208022h0001 (TH) and by GSK Japan Research grant 2017 (TH).

440

441

442

443 **References**

- 444 1. Griffin D. 2013. Measles virus, p 1042 – 1069. *In* Knipe D, Howley P, Cohen J, Griffin  
445 D, Lamb R, Martin M, Racaniello V, Roizman B (ed), *Fields virology*, 6th ed. Lippincott  
446 Williams & Wilkins, Philadelphia, PA.
- 447 2. Coughlin MM, Beck AS, Bankamp B, Rota PA. 2017. Perspective on Global Measles  
448 Epidemiology and Control and the Role of Novel Vaccination Strategies. *Viruses* 9:11.
- 449 3. Bellini WJ, Rota JS, Lowe LE, Katz RS, Dyken PR, Zaki SR, Shieh W-J, Rota PA. 2005.  
450 Subacute Sclerosing Panencephalitis: More Cases of This Fatal Disease Are Prevented  
451 by Measles Immunization than Was Previously Recognized. *The Journal of Infectious*  
452 *Diseases* 192:1686-1693.
- 453 4. Schönberger K, Ludwig M-S, Wildner M, Weissbrich B. 2013. Epidemiology of Subacute  
454 Sclerosing Panencephalitis (SSPE) in Germany from 2003 to 2009: A Risk Estimation.  
455 *PLOS ONE* 8:e68909.
- 456 5. Gutierrez J, Issacson RS, Koppel BS. 2010. Subacute sclerosing panencephalitis: an  
457 update. *Dev Med Child Neurol* 52:901-7.
- 458 6. Hashiguchi T, Ose T, Kubota M, Maita N, Kamishikiryo J, Maenaka K, Yanagi Y. 2011.  
459 Structure of the measles virus hemagglutinin bound to its cellular receptor SLAM. *Nat*  
460 *Struct Mol Biol* 18:135-41.
- 461 7. Plattet P, Alves L, Herren M, Aguilar H. 2016. Measles Virus Fusion Protein: Structure,  
462 Function and Inhibition. *Viruses* 8:112.
- 463 8. Tatsuo H, Ono N, Tanaka K, Yanagi Y. 2000. SLAM (CDw150) is a cellular receptor for  
464 measles virus. *Nature* 406:893-7.
- 465 9. Ono N, Tatsuo H, Hidaka Y, Aoki T, Minagawa H, Yanagi Y. 2001. Measles Viruses on  
466 Throat Swabs from Measles Patients Use Signaling Lymphocytic Activation Molecule  
467 (CDw150) but Not CD46 as a Cellular Receptor. *Journal of Virology* 75:4399-4401.
- 468 10. Noyce RS, Bondre DG, Ha MN, Lin LT, Sisson G, Tsao MS, Richardson CD. 2011. Tumor  
469 cell marker PVRL4 (nectin 4) is an epithelial cell receptor for measles virus. *PLoS*  
470 *Pathog* 7:e1002240.
- 471 11. Muhlebach MD, Mateo M, Sinn PL, Prufer S, Uhlig KM, Leonard VHJ, Navaratnarajah  
472 CK, Frenzke M, Wong XX, Sawatsky B, Ramachandran S, McCray PB, Cichutek K, von  
473 Messling V, Lopez M, Cattaneo R. 2011. Adherens junction protein nectin-4 is the  
474 epithelial receptor for measles virus. *Nature* 480:530-533.

- 475 12. McQuaid S, Cosby SL. 2002. An Immunohistochemical Study of the Distribution of the  
476 Measles Virus Receptors, CD46 and SLAM, in Normal Human Tissues and Subacute  
477 Sclerosing Panencephalitis. *Lab Invest* 82:403-409.
- 478 13. Reymond N, Fabre S, Lecocq E, Adelaïde J, Dubreuil P, Lopez M. 2001. Nectin4/PRR4, a  
479 New Afadin-associated Member of the Nectin Family That Trans-interacts with  
480 Nectin1/PRR1 through V Domain Interaction. *Journal of Biological Chemistry*  
481 276:43205-43215.
- 482 14. Paula-Barbosa MM, Cruz C. 1981. Nerve cell fusion in a case of subacute sclerosing  
483 panencephalitis. *Ann Neurol* 9:400-3.
- 484 15. Lewandowska E, Lechowicz W, Szpak GM, Sobczyk W. 2001. Quantitative evaluation of  
485 intranuclear inclusions in SSPE: correlation with disease duration. *Folia Neuropathol*  
486 39:237-41.
- 487 16. Godec MS, Asher DM, Swoveland PT, Eldadah ZA, Feinstone SM, Goldfarb LG, Gibbs  
488 CJ, Jr., Gajdusek DC. 1990. Detection of measles virus genomic sequences in SSPE  
489 brain tissue by the polymerase chain reaction. *J Med Virol* 30:237-44.
- 490 17. Kühne Simmonds M, Brown DWG, Jin L. 2006. Measles viral load may reflect SSPE  
491 disease progression. *Virology Journal* 3:49.
- 492 18. Lecouturier V, Fayolle J, Caballero M, Carabana J, Celma ML, Fernandez-Munoz R,  
493 Wild TF, Buckland R. 1996. Identification of two amino acids in the hemagglutinin  
494 glycoprotein of measles virus (MV) that govern hemadsorption, HeLa cell fusion, and  
495 CD46 downregulation: phenotypic markers that differentiate vaccine and wild-type MV  
496 strains. *J Virol* 70:4200-4.
- 497 19. Tahara M, Takeda M, Seki F, Hashiguchi T, Yanagi Y. 2007. Multiple Amino Acid  
498 Substitutions in Hemagglutinin Are Necessary for Wild-Type Measles Virus To Acquire  
499 the Ability To Use Receptor CD46 Efficiently. *Journal of Virology* 81:2564-2572.
- 500 20. Lawrence DM, Patterson CE, Gales TL, D'Orazio JL, Vaughn MM, Rall GF. 2000.  
501 Measles virus spread between neurons requires cell contact but not CD46 expression,  
502 syncytium formation, or extracellular virus production. *J Virol* 74:1908-18.
- 503 21. Makhortova NR, Askovich P, Patterson CE, Gechman LA, Gerard NP, Rall GF. 2007.  
504 Neurokinin-1 enables measles virus trans-synaptic spread in neurons. *Virology*  
505 362:235-244.
- 506 22. Young VA, Rall GF. 2009. Making it to the synapse: Measles virus spread in and among  
507 neurons. *Current topics in microbiology and immunology* 330:3-30.

- 508 23. Ehrengreuber MU, Ehler E, Billeter MA, Naim HY. 2002. Measles Virus Spreads in Rat  
509 Hippocampal Neurons by Cell-to-Cell Contact and in a Polarized Fashion. *Journal of*  
510 *Virology* 76:5720-5728.
- 511 24. Cattaneo R, Schmid A, Rebmann G, Baczko K, Ter Meulen V, Bellini WJ, Rozenblatt S,  
512 Billeter MA. 1986. Accumulated measles virus mutations in a case of subacute  
513 sclerosing panencephalitis: interrupted matrix protein reading frame and transcription  
514 alteration. *Virology* 154:97-107.
- 515 25. Ayata M, Komase K, Shingai M, Matsunaga I, Katayama Y, Ogura H. 2002. Mutations  
516 Affecting Transcriptional Termination in the P Gene End of Subacute Sclerosing  
517 Panencephalitis Viruses. *Journal of Virology* 76:13062-13068.
- 518 26. Patterson JB, Cornu TI, Redwine J, Dales S, Lewicki H, Holz A, Thomas D, Billeter MA,  
519 Oldstone MB. 2001. Evidence that the hypermutated M protein of a subacute sclerosing  
520 panencephalitis measles virus actively contributes to the chronic progressive CNS  
521 disease. *Virology* 291:215-25.
- 522 27. Cathomen T, Mrkic B, Spehner D, Drillien R, Naef R, Pavlovic J, Aguzzi A, Billeter MA,  
523 Cattaneo R. 1998. A matrix-less measles virus is infectious and elicits extensive cell  
524 fusion: consequences for propagation in the brain. *The EMBO Journal* 17:3899-3908.
- 525 28. Suryanarayana K, Baczko K, ter Meulen V, Wagner RR. 1994. Transcription inhibition  
526 and other properties of matrix proteins expressed by M genes cloned from measles  
527 viruses and diseased human brain tissue. *J Virol* 68:1532-43.
- 528 29. Reuter T, Weissbrich B, Schneider-Schaulies S, Schneider-Schaulies J. 2006. RNA  
529 interference with measles virus N, P, and L mRNAs efficiently prevents and with matrix  
530 protein mRNA enhances viral transcription. *J Virol* 80:5951-7.
- 531 30. Cattaneo R, Schmid A, Eschle D, Baczko K, ter Meulen V, Billeter MA. 1988. Biased  
532 hypermutation and other genetic changes in defective measles viruses in human brain  
533 infections. *Cell* 55:255-65.
- 534 31. Schmid A, Spielhofer P, Cattaneo R, Baczko K, ter Meulen V, Billeter MA. 1992.  
535 Subacute sclerosing panencephalitis is typically characterized by alterations in the  
536 fusion protein cytoplasmic domain of the persisting measles virus. *Virology* 188:910-5.
- 537 32. Ayata M, Takeuchi K, Takeda M, Ohgimoto S, Kato S, Sharma LB, Tanaka M,  
538 Kuwamura M, Ishida H, Ogura H. 2010. The F Gene of the Osaka-2 Strain of Measles  
539 Virus Derived from a Case of Subacute Sclerosing Panencephalitis Is a Major  
540 Determinant of Neurovirulence. *Journal of Virology* 84:11189-11199.

- 541 33. Watanabe S, Shirogane Y, Suzuki SO, Ikegame S, Koga R, Yanagi Y. 2013. Mutant  
542 fusion proteins with enhanced fusion activity promote measles virus spread in human  
543 neuronal cells and brains of suckling hamsters. *J Virol* 87:2648-59.
- 544 34. Watanabe S, Ohno S, Shirogane Y, Suzuki SO, Koga R, Yanagi Y. 2015. Measles Virus  
545 Mutants Possessing the Fusion Protein with Enhanced Fusion Activity Spread  
546 Effectively in Neuronal Cells, but Not in Other Cells, without Causing Strong  
547 Cytopathology. *Journal of Virology* 89:2710-2717.
- 548 35. Cattaneo R, Rose JK. 1993. Cell fusion by the envelope glycoproteins of persistent  
549 measles viruses which caused lethal human brain disease. *Journal of Virology*  
550 67:1493-1502.
- 551 36. Honda T, Yoneda M, Sato H, Kai C. 2013. Pathogenesis of Encephalitis Caused by  
552 Persistent Measles Virus Infection, p Ch. 14. *In* Tkachev S (ed), *Encephalitis*. InTech,  
553 Rijeka.
- 554 37. Andrews PW. 1984. Retinoic acid induces neuronal differentiation of a cloned human  
555 embryonal carcinoma cell line in vitro. *Developmental Biology* 103:285-293.
- 556 38. Pleasure SJ, Page C, Lee VM. 1992. Pure, postmitotic, polarized human neurons derived  
557 from NTera 2 cells provide a system for expressing exogenous proteins in terminally  
558 differentiated neurons. *J Neurosci* 12:1802-15.
- 559 39. Cheung WM, Fu WY, Hui WS, Ip NY. 1999. Production of human CNS neurons from  
560 embryonal carcinoma cells using a cell aggregation method. *Biotechniques* 26:946-8,  
561 950-2, 954.
- 562 40. Paquet-Durand F, Tan S, Bicker G. 2003. Turning teratocarcinoma cells into neurons:  
563 rapid differentiation of NT-2 cells in floating spheres. *Developmental Brain Research*  
564 142:161-167.
- 565 41. Podrygajlo G, Tegenge MA, Gierse A, Paquet-Durand F, Tan S, Bicker G, Stern M. 2009.  
566 Cellular phenotypes of human model neurons (NT2) after differentiation in aggregate  
567 culture. *Cell Tissue Res* 336:439-52.
- 568 42. Podrygajlo G, Song Y, Schlesinger F, Krampfl K, Bicker G. 2010. Synaptic currents and  
569 transmitter responses in human NT2 neurons differentiated in aggregate culture.  
570 *Neuroscience Letters* 468:207-210.
- 571 43. Paquet-Durand F, Bicker G. 2007. Human model neurons in studies of brain cell  
572 damage and neural repair. *Curr Mol Med* 7:541-54.
- 573 44. Rima BK, Earle JA, Baczkko K, ter Meulen V, Liebert UG, Carstens C, Carabana J,

574 Caballero M, Celma ML, Fernandez-Munoz R. 1997. Sequence divergence of measles  
575 virus haemagglutinin during natural evolution and adaptation to cell culture. *J Gen*  
576 *Viro* 78 ( Pt 1):97-106.

577 45. Shingai M, Ayata M, Ishida H, Matsunaga I, Katayama Y, Seya T, Tatsuo H, Yanagi Y,  
578 Ogura H. 2003. Receptor use by vesicular stomatitis virus pseudotypes with  
579 glycoproteins of defective variants of measles virus isolated from brains of patients with  
580 subacute sclerosing panencephalitis. *J Gen Virol* 84:2133-43.

581 46. Hotta H, Nihei K, Abe Y, Kato S, Jiang DP, Nagano-Fujii M, Sada K. 2006. Full-length  
582 sequence analysis of subacute sclerosing panencephalitis (SSPE) virus, a mutant of  
583 measles virus, isolated from brain tissues of a patient shortly after onset of SSPE.  
584 *Microbiol Immunol* 50:525-34.

585 47. Takada A, Robison C, Goto H, Sanchez A, Murti KG, Whitt MA, Kawaoka Y. 1997. A  
586 system for functional analysis of Ebola virus glycoprotein. *Proc Natl Acad Sci U S A*  
587 94:14764-9.

588 48. Richardson CD, Scheid A, Choppin PW. 1980. Specific inhibition of paramyxovirus and  
589 myxovirus replication by oligopeptides with amino acid sequences similar to those at the  
590 N-termini of the F1 or HA2 viral polypeptides. *Virology* 105:205-222.

591 49. Harrowe G, Mitsuhashi M, Payan DG. 1990. Measles virus-substance P receptor  
592 interactions. Possible novel mechanism of viral fusion. *J Clin Invest* 85:1324-7.

593 50. Tahara M, Ohno S, Sakai K, Ito Y, Fukuhara H, Komase K, Brindley MA, Rota PA,  
594 Plemper RK, Maenaka K, Takeda M. 2013. The Receptor-Binding Site of the Measles  
595 Virus Hemagglutinin Protein Itself Constitutes a Conserved Neutralizing Epitope.  
596 *Journal of Virology* 87:3583-3586.

597 51. Welsch JC, Talekar A, Mathieu C, Pessi A, Moscona A, Horvat B, Porotto M. 2013. Fatal  
598 Measles Virus Infection Prevented by Brain-Penetrant Fusion Inhibitors. *Journal of*  
599 *Virology* 87:13785-13794.

600 52. Mathieu C, Huey D, Jurgens E, Welsch JC, DeVito I, Talekar A, Horvat B, Niewiesk S,  
601 Moscona A, Porotto M. 2015. Prevention of measles virus infection by intranasal  
602 delivery of fusion inhibitor peptides. *J Virol* 89:1143-55.

603 53. Figueira TN, Palermo LM, Veiga AS, Huey D, Alabi CA, Santos NC, Welsch JC, Mathieu  
604 C, Horvat B, Niewiesk S, Moscona A, Castanho MA, Porotto M. 2017. In Vivo Efficacy of  
605 Measles Virus Fusion Protein-Derived Peptides Is Modulated by the Properties of  
606 Self-Assembly and Membrane Residence. *J Virol* 91.



- 607 54. Jurgens EM, Mathieu C, Palermo LM, Hardie D, Horvat B, Moscona A, Porotto M. 2015.  
608 Measles Fusion Machinery Is Dysregulated in Neuropathogenic Variants. *mBio* 6.
- 609 55. Otsuki N, Sekizuka T, Seki F, Sakai K, Kubota T, Nakatsu Y, Chen S, Fukuhara H,  
610 Maenaka K, Yamaguchi R, Kuroda M, Takeda M. 2013. Canine distemper virus with the  
611 intact C protein has the potential to replicate in human epithelial cells by using human  
612 nectin4 as a receptor. *Virology* 435:485-492.
- 613 56. Takeda M, Takeuchi K, Miyajima N, Kobune F, Ami Y, Nagata N, Suzaki Y, Nagai Y,  
614 Tashiro M. 2000. Recovery of Pathogenic Measles Virus from Cloned cDNA. *Journal of*  
615 *Virology* 74:6643-6647.
- 616 57. Hashimoto K, Ono N, Tatsuo H, Minagawa H, Takeda M, Takeuchi K, Yanagi Y. 2002.  
617 SLAM (CD150)-Independent Measles Virus Entry as Revealed by Recombinant Virus  
618 Expressing Green Fluorescent Protein. *Journal of Virology* 76:6743-6749.
- 619 58. Seki F, Yamada K, Nakatsu Y, Okamura K, Yanagi Y, Nakayama T, Komase K, Takeda  
620 M. 2011. The SI Strain of Measles Virus Derived from a Patient with Subacute  
621 Sclerosing Panencephalitis Possesses Typical Genome Alterations and Unique Amino  
622 Acid Changes That Modulate Receptor Specificity and Reduce Membrane Fusion  
623 Activity. *Journal of Virology* 85:11871-11882.
- 624 59. Tatsuo H, Okuma K, Tanaka K, Ono N, Minagawa H, Takade A, Matsuura Y, Yanagi Y.  
625 2000. Virus Entry Is a Major Determinant of Cell Tropism of Edmonston and Wild-Type  
626 Strains of Measles Virus as Revealed by Vesicular Stomatitis Virus Pseudotypes  
627 Bearing Their Envelope Proteins. *Journal of Virology* 74:4139-4145.
- 628 60. Reeves PJ, Callewaert N, Contreras R, Khorana HG. 2002. Structure and function in  
629 rhodopsin: high-level expression of rhodopsin with restricted and homogeneous  
630 N-glycosylation by a tetracycline-inducible N-acetylglucosaminyltransferase I-negative  
631 HEK293S stable mammalian cell line. *Proc Natl Acad Sci U S A* 99:13419-24.
- 632 61. Hashiguchi T, Kajikawa M, Maita N, Takeda M, Kuroki K, Sasaki K, Kohda D, Yanagi Y,  
633 Maenaka K. 2007. Crystal structure of measles virus hemagglutinin provides insight  
634 into effective vaccines. *Proc Natl Acad Sci U S A* 104:19535-40.
- 635 62. Yanagi Y, Cubitt BA, Oldstone MBA. 1992. Measles virus inhibits mitogen-induced T  
636 cell proliferation but does not directly perturb the T cell activation process inside the  
637 cell. *Virology* 187:280-289.

638

639 **Figure Legends**

640 **Figure 1. Neuronal differentiation of NT2 cells.** (A) Phase-contrast images of  
641 undifferentiated NT2 cells and postmitotic NT2 neurons (NT2N). For neuronal  
642 differentiation, NT2 cells were treated with RA for 2 weeks, and mitotic  
643 inhibitors for additional 1 week. NT2 neurons tended to form clusters (arrow).  
644 There were a small number of glia-like cells in the postmitotic cell population  
645 (arrowhead). Scale bar, 250  $\mu$ m. (B) Relative gene expression levels of neuronal  
646 (MAP2, MAPT, RBFOX3, and TUBB3) and astrocytic (GFAP and GLUL)  
647 markers in NT2 and NT2N cells were quantified by RT-qPCR. Data were  
648 normalized to those of GAPDH and presented as mean  $\pm$  standard error of the  
649 mean (SEM) of three independent experiments. Asterisks indicate statistically  
650 significant increases compared with NT2 ( $P < 0.05$ ).

651

652 **Figure 2. Spread of recombinant MVs in NT2N cells.** (A) NT2N cells were  
653 infected with IC323-EGFP or IC323-F(T461I)-EGFP at an MOI of 2. NT2N cells  
654 were also infected with VSV $\Delta$ G\*-G at an MOI of 0.05. The cells were observed  
655 under a light and a fluorescence microscope at 1 and 2 d.p.i. Representative

656 images are shown. The same areas were photographed each day. Arrowheads  
657 indicate the same infected cell in IC323-EGFP- or VSV $\Delta$ G\*-G-infected NT2N  
658 cells, respectively. Scale bar, 250  $\mu$ m. **(B)** NT2N cells were infected with  
659 IC323-EGFP or IC323-F(T461I)-EGFP at an MOI of 2, and cell lysates were  
660 collected at the indicated time points. The samples were subjected to  
661 SDS-PAGE and Western blotting using an antibody against the N protein  
662 (MV-N). Actin was used as a loading control. Relative expression levels of the N  
663 protein normalized to that of actin are indicated for each time point. The value  
664 of 3 h p.i. was set to 1 for each virus. (-), uninfected.

665

666 **Figure 3. Cell-to-cell spread of the hyperfusogenic virus in NT2N cells. (A)**  
667 NT2N cells were infected with IC323-F(T461I)-EGFP at an MOI of 2, and  
668 observed by confocal time-lapse imaging. Arrowheads indicate the spread of  
669 EGFP expression from an infected neuron to an adjacent cell. See also Movie S1  
670 in the supplemental material. **(B)** Growth kinetics of IC323-F(T461I)-EGFP in  
671 NT2N cells. NT2N cells were infected as in (A). Supernatants and cells were  
672 harvested at 3, 24, 48, 72, and 96 h p.i. Virus titer (combined titer of

673 cell-associated and cell-free viruses) at each time point was determined by  
674 plaque assay. Data are shown as mean  $\pm$  standard deviation (SD) of triplicate  
675 samples. The dotted line depicts the detection limit.

676


677 **Figure 4. Spread of the hyperfusogenic virus is inhibited by FIP.** Vero/hSLAM  
678 and NT2N cells were infected with IC323-F(T461I)-EGFP at an MOI of 0.1. At 1  
679 h p.i., FIP or the solvent DMSO was added to the culture medium at a final  
680 concentration of 200  $\mu$ M. The cells were observed under a light and a  
681 fluorescence microscope at the indicated day after infection. The panels show  
682 representative images. Scale bar, 250  $\mu$ m.

683

684 **Figure 5. Spread of the hyperfusogenic virus is inhibited by anti-hemagglutinin**  
685 **antibodies.** Cells were seeded in 96-well plates. Vero/hSLAM and Vero/hNectin4  
686 cells were infected with IC323-EGFP and NT2N cells with  
687 IC323-F(T461I)-EGFP at an MOI of 0.1 in triplicate. At 1 h p.i., the indicated  
688 MAbs against the MV-H protein were added to the culture medium. As a  
689 negative control, anti-H MAb 5G7, which has no ability to neutralize MV, was


690 used. EGFP fluorescence was observed under a fluorescence microscope at 48 h  
691 p.i. **(A)** Fluorescence image of a representative well is shown for each sample.  
692 Ab(-), no antibody. **(B)** Relative areas of EGFP-expressing cells in each well were  
693 quantified by imaging software. Data are shown as mean  $\pm$  SD of triplicate  
694 samples. The value of Ab(-) was set to 1 for each cell type.

Figure 1




**Figure 1. Neuronal differentiation of NT2 cells.** (A) Phase-contrast images of undifferentiated NT2 cells and postmitotic NT2 neurons (NT2N). For neuronal differentiation, NT2 cells were treated with RA for 2 weeks, and mitotic inhibitors for additional 1 week. NT2 neurons tended to form clusters (arrow). There were a small number of glia-like cells in the postmitotic cell population (arrowhead). Scale bar, 250  $\mu$ m. (B) Relative gene expression levels of neuronal (MAP2, MAPT, RBFOX3, and TUBB3) and astrocytic (GFAP and GLUL) markers in NT2 and NT2N cells were quantified by RT-qPCR. Data were normalized to those of GAPDH and presented as mean  $\pm$  standard error of the mean (SEM) of three independent experiments. Asterisks indicate statistically significant increases compared with NT2 ( $P < 0.05$ ).

Figure 2



**Figure 2. Spread of recombinant MVs in NT2N cells.** (A) NT2N cells were infected with IC323-EGFP or IC323-F(T461I)-EGFP at an MOI of 2. NT2N cells were also infected with VSVΔG\*-G at an MOI of 0.05. The cells were observed under a light and a fluorescence microscope at 1 and 2 d.p.i. Representative images are shown. The same areas were photographed each day. Arrowheads indicate the same infected cell in IC323-EGFP- or VSVΔG\*-G-infected NT2N cells, respectively. Scale bar, 250 μm. (B) NT2N cells were infected with IC323-EGFP or IC323-F(T461I)-EGFP at an MOI of 2, and cell lysates were collected at the indicated time points. The samples were subjected to SDS-PAGE and Western blotting using an antibody against the N protein (MV-N). Actin was used as a loading control. Relative expression levels of the N protein normalized to that of actin are indicated for each time point. The value of 3 h p.i. was set to 1 for each virus. (-), uninfected.


Figure 3



**Figure 3. Cell-to-cell spread of the hyperfusogenic virus in NT2N cells.** (A) NT2N cells were infected with IC323-F(T461D)-EGFP at an MOI of 2, and observed by confocal time-lapse imaging. Arrowheads indicate the spread of EGFP expression from an infected neuron to an adjacent cell. See also Movie S1 in the supplemental material. (B) Growth kinetics of IC323-F(T461D)-EGFP in NT2N cells. NT2N cells were infected as in (A). Supernatants and cells were harvested at 3, 24, 48, 72, and 96 h p.i. Virus titer (combined titer of cell-associated and cell-free viruses) at each time point was determined by plaque assay. Data are shown as mean  $\pm$  standard deviation (SD) of triplicate samples. The dotted line depicts the detection limit.




Figure 4



**Figure 4. Spread of the hyperfusogenic virus is inhibited by FIP.** Vero/hSLAM and NT2N cells were infected with IC323-F(T461I)-EGFP at an MOI of 0.1. At 1 h p.i., FIP or the solvent DMSO was added to the culture medium at a final concentration of 200  $\mu$ M. The cells were observed under a light and a fluorescence microscope at the indicated day after infection. The panels show representative images. Scale bar, 250  $\mu$ m.

Figure 5



**Figure 5. Spread of the hyperfusogenic virus is inhibited by anti-hemagglutinin antibodies.** Cells were seeded in 96-well plates. Vero/hSLAM and Vero/hNectin4 cells were infected with IC323-EGFP and NT2N cells with IC323-F(T461D)-EGFP at an MOI of 0.1 in triplicate. At 1 h p.i., the indicated MAbs against the MV-H protein were added to the culture medium. As a negative control, anti-H MAb 5G7, which has no ability to neutralize MV, was used. EGFP fluorescence was observed under a fluorescence microscope at 48 h p.i. (A) Fluorescence image of a representative well is shown for each sample. Ab(-), no antibody. (B) Relative areas of EGFP-expressing cells in each well were quantified by imaging software. Data are shown as mean  $\pm$  SD of triplicate samples. The value of Ab(-) was set to 1 for each cell type.